No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The prasugrel label specifies no renal dose reduction. ESRD experience is limited and bleeding risk in that population is increased. Limits and monitoring Review bleeding risk, prior stroke or TIA, age and body weight independently of renal function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Sep 09, 2022 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure CrCl normalized to 1.73 m2, mL/min/1.73 m2 Renal action or finding A single oral 20 mg dose of rabeprazole produced similar pharmacokinetic findings in stable ESRD on maintenance HD and in controls. Limits and monitoring Single-dose data do not establish a supplemental dose or HD timing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 3, posted Jan 30, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Use caution with raloxifene in moderate or severe renal impairment because safety and efficacy have not been established in these groups. Limits and monitoring The cited evidence supplies no validated dose reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 32, posted Sep 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The label does not require a renal dose change for raltegravir. Limits and monitoring The presentations have different dosing and substitution instructions. Verify product and strength. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 71, posted Oct 15, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Ramelteon requires no renal reduction, including in severe impairment and chronic hemodialysis. Limits and monitoring This is the oral insomnia product. Review hepatic function and interacting medicines separately. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 20, posted Apr 27, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding In the population analysis, Cockcroft-Gault CrCl 15-89 mL/min had no clinically meaningful effect on the antibody's pharmacokinetics. Limits and monitoring The analysis does not establish a dialysis dose. Review the product-specific toxicity precautions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 48, posted Jun 10, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild or moderate renal impairment does not require a rasagiline dose change. Severe impairment has not been studied. Limits and monitoring Check interacting medications and the labeled hepatic restrictions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 26, posted Sep 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For adult DVT/PE treatment, avoid rivaroxaban if CrCl is below 15 mL/min. At 15 to below 30, evidence is limited and bleeding warrants close evaluation. Limits and monitoring Use the table for the specific indication. The AF, CAD/PAD and pediatric instructions have different eligibility and dosing assumptions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 65, posted Sep 11, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Oral roflumilast requires no renal adjustment, including in the severe-impairment population studied. Limits and monitoring Review the product's hepatic restrictions and tolerability separately. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 15, posted Dec 19, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Single-agent rosiglitazone requires no renal dose change. Limits and monitoring Combination tablets containing metformin have separate renal restrictions. Review fluid retention and heart failure. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 1, posted Feb 25, 2010 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding There are no pharmacokinetic data for sacituzumab govitecan at CrCl 15-29 mL/min or below 15 mL/min. Limits and monitoring Use the product's toxicity instructions. The evidence gap supplies no dialysis regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 20, posted Jun 29, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure MDRD eGFR, mL/min as printed in this label Renal action or finding The source specifies usual selpercatinib dosing for MDRD eGFR 15-89 mL/min. An ESRD dose has not been established. Limits and monitoring Use the renal method and units printed in this label. Confirm the prescribed tablet or capsule. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 25, posted Sep 14, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
